Summary.-One hundred and sixty women admitted for breast tumour biopsy to the King's College Hospital group have been followed sequentially for 2 years. Sixty-nine women had early operable breast cancer and 91 had benign breast disease. All these women had serum immunoglobulin IgG, IgA, IgM and IgE levels measured preoperatively and postoperatively at 3 months, 1 year and 2 years. No differences were found in any of the serum immunoglobulin levels between the two groups at any time. There was, however, a positive correlation between the extent of metastatic breast cancer and the serum level of various immunoglobulins, particularly IgA. There was no evidence that routine postoperative radiotherapy influenced the levels of serum immunoglobulins. The findings suggest a secondary defence reaction against increasing tumour load, and do not support the theory of an early immune defect in immunoglobulin metabolism which could play a part in the pathogenesis of breast cancer. Although there is no diagnostic value in measuring the levels of serum immunoglobulins in patients with breast tumours, there may be some value in following the levels in cancer patients, as a guide to subclinical spread of the disease.
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THERE is evidence that the measurement of serum immunoglobulin levels may be useful in the management of cancer patients in three separate ways: as a diagnostic indicator, as an indicator of tumour spread or as an indicator of immunosuppression in the pathogenesis of cancer.
In a large survey of patients suffering from various non-haematopoietic cancers, serum levels of the immunoglobulins IgG, IgA and IgM were found to be altered (Hughes, 1971) . Patients with carcinomas of the skin and lung had elevated serum levels of IgG and IgA, whereas patients with tumours of the gastrointestinal tract and uterus had increased serum levels of IgA only. Serum levels of IgM were unaffected, except in male patients with sarcomas and female patients with melanoma.
Although the above study did not find differences in the levels of serum immunoglobulins in patients with breast cancer, two other studies have reported higher serum levels of IgA in breast cancer patients than in control patients with benign breast disease (Rowinska-Zakrewska, Lazar and Burtin, 1970; Roberts, Bathgate and Stevenson, 1975) . It has also been suggested that patients with breast cancer who have increased levels of serum IgA before mastectomy have an improved prognosis (Meyer, Mackler and Beck, 1973) .
Patients with breast cancer have been reported to suffer significantly less from allergic diseases than do controls without cancer (Mackay, 1966) . The relationship of this observation to the pathogenesis of cancer is unknown, although there is some evidence that atopic subjects are "high responders" (i.e. more readily make antibodies to foreign substances than do non-atopic subjects (Platts-Mills et al., 1976) ).
Cancer patients were found to have slightly lower than normal IgE levels, according to single radial immunodiffusion (Augustin and Chandradasa, 1971 ) and so they might possibly be regarded as "low responders". However, normal IgE levels are much lower (Nye et al., 1975) than was originally believed, and are below the limits of immunodiffusion procedures.
The value of previous studies has been limited by a number of factors. Firstly, no study has reported changes in serum immunoglobulin levels followed serially in the same subjects over an extended period of time. Secondly, only rarely has the extent of the disease been considered or the effects of potentially immunosuppressive therapy (e.g. radiotherapy or cytotoxic drugs). Finally, although the distributions of each of the serum immunoglobulin levels is lognormal, statistical comparisons have been made on data without logarithmic transformation.
This study was undertaken to determine (a) whether the serum levels of immunoglobulins IgG, IgA, IgM and IgE changed in early breast cancer compared to nonmalignant breast disease: (b) whether changes in serum levels of immunoglobulins could be correlated with the spread of the tumour. The results of the first 2 years are reported here.
PATIENTS AND METHODS
One hundred and sixty women admitted to King's College Hospital for breast tumour biopsy have been studied. Sixty-nine of these women were found to have breast cancer and 91 non-malignant breast disease.
All the women were less than 70 years of age and had breast lumps less than 5 cm in diameter, with or without palpable ipsilateral axillary glands. Those with breast cancer therefore had tumours which fell into Clinical Stage I or II of the Manchester classification (Wise, Mason and Ackerman, 1971) and had no evidence of clinically 37 occult mietastases as shown by routine chest X-ray, liver function tests and serum chemistry or bone scanning.
The 2 groups of women had venous blood sampled the day before operation, and subsequently they have had further samples taken 3 months postoperatively and then annually for between 2 and 3 years.
A careful clinical record has been kept of each cancer patient. A system for quantifying the approximate tumour mass in each cancer patient was devised to produce the clinical score, so that correlations between the immunoglobulin levels and the extent of the cancer could be performed. This scoring system was based upon the diameter of the breast tumour measured postoperatively, and additional points were given for evidence of histological spread of the tumour to involve skin, pectoral muscles or lymph nodes. Postoperatively the score was increased for local recurrence of the tumour in the scar or lymph nodes and for the development of each metastatic lesion confirmed by biopsy. Equal weighting was given to proven metastases, irrespective of site, and the score modified if a lesion increased or decreased in size. A reduced weighting was given to symptoms or investigations which suggested metastatic spread, before a lesion was confirmed (e.g., persistent backache). Details of the scoring system are given in an Appendix. Serum was separated from the blood samples, divided into aliquots, coded and stored at -20°C. Samples were randomized and analysed in batches of 50. Estimations of immunoglobulins IgG, IgA and IgM were made, using single radial immunodiffusion on commercial Tripartigen plates (Hoechst Ltd). Total serum IgE levels were measured using radioimmunoassay as previously described in detail (Merrett and Pantin, 1975) . Serum IgE levels were measured in only 100 patients preoperatively and 110 patients at follow-up.
RESULTS

A. Comparison between the two diagnostic populations
The serum levels of immunoglobulins G, A, M and E in breast cancer patients were not significantly different from the 3. Preoperative elevation of serum IgG level (> 2 g/100 ml) was usually associated with early metastatic disease (4/5 patients).
4. Preoperative elevation of serum IgA level (> 450 mg/100 ml) was rarely associated with metastatic disease in the first 2 years (1/7) particularly if the serum level fell progressively.
D. The effect8 of therapy on serum immunoglobulin levels
The patients with breast cancer were allocated at random to one of 2 treatment groups in the King's/Cambridge breast trial (Baum, Edwards and Magarey, 1972) , and 25 patients received routine postoperative radiotherapy to the ipsilateral axillary nodes between the time of mastectomy and the 3-month follow-up sample. These patients as a group had significantly lower mean serum IgM and IgE levels preoperatively, and also significantly lower mean serum lgM levels at 3 and 12 months postoperatively, than in breast cancer patients who did not receive radiotherapy (Table III) . There was no evidence that the group not receiving radiotherapy were clinically more advanced than those who did not.
(No IgE levels were measured at 2 years postoperatively.)
Individual patients who subsequently developed metastatic breast cancer received various additional forms of therapy, including radiotherapy, chemotherapy and hormone-replacement therapy. Although reductions in some of the immunoglobulin levels were seen, especially in serum IgG, it was not possible to separate the effects of the therapy from those of the disease process.
DISCUSSION
This study has not demonstrated any alteration in the levels of serum immunoglobulins IgG, IgA, IgM or IgE in patients with breast cancer relative to patients with benign breast lumps, when followed prospectively for 2 years. We have not, Roberts et al. (1975) . However, the patients in our study were especially selected to be at the earliest clinical stage of their disease and, since serum IgA levels may rise with advancing disease, this difference in the selection of patients, plus the statistical analysis on logarithmically transformed data, mav account for our differing results.
The model IgE value in a non-atopic population was found to be 21 u/ml (Nye et al., 1975) and 38 u/ml in a population of mean to base 10 expressed in mg/100 ml for that excluded asthma and chronic bronchitis sufferers (Burr et al., 1975 (Tee and Pettingale, unpublished) .
In addition, we have found diverse changes in other serum proteins in our patients with breast cancer (Pettingale and Tee, 1977) 
